T-cell costimulation–biology, therapeutic potential, and challenges.
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
The immune system has the remarkable ability to defend against diverse microbial pathogens and yet not to respond to self. T cells are key mediators of the immune response, and their activation is tightly regulated to prevent autoreactivity. The processes of T-cell activation and self-tolerance are therefore potential targets for manipulation by drugs — hence, the recent phase 1 trial of a “superagonistic” monoclonal anti-CD28 antibody that was conducted in Britain on behalf of the German firm TeGenero, with the unexpected and devastating results described by Suntharalingam et al. in this issue of the Journal (pages 1018–1028).T-cell activation requires . . .
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“According to the currently accepted model of T cell activation, two signals are required to fully activate resting naïve T lymphocytes.”
From Signaling Signatures and Functional Properties of Anti-Human CD28 Superagonistic Antibodies (2008) · cites this paper as [2]
Citations
Cites
Greenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318
Self-citationCytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164
Natural versus adaptive regulatory T cells
Bluestone, J. A., & Abbas, A. K. (2003) · Nature Reviews Immunology · doi:10.1038/nri1032 · Cited by 1,323
Self-citationCTLA4Ig: Bridging the Basic Immunology with Clinical Application
Bluestone, J. A., St. Clair, E. W., & Turka, L. A. (2006) · Immunity · doi:10.1016/j.immuni.2006.03.001 · Cited by 276
Beyersdorf, N., Gaupp, S., Balbach, K., Schmidt, J., Toyka, K. V., Lin, C.-H., Hanke, T., Hünig, T., Kerkau, T., & Gold, R. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051060 · Cited by 203
CD28 superagonists: Mode of action and therapeutic potential
Hünig, T., & Dennehy, K. M. (2005) · Immunology Letters · doi:10.1016/j.imlet.2005.06.012 · Cited by 63
Drazen, J. M. (2006) · New England Journal of Medicine · doi:10.1056/nejme068175 · Cited by 13
Cited by
The safety and side effects of monoclonal antibodies
Hansel, T. T., Kropshofer, H., Singer, T., Mitchell, J. A., & George, A. J. T. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3003 · Cited by 1,144
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
Boutros, C., Tarhini, A., Routier, E., Lambotte, O., Ladurie, F. L., Carbonnel, F., Izzeddine, H., Marabelle, A., Champiat, S., Berdelou, A., et al. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.58 · Cited by 1,102
Mechanism of action of lenalidomide in hematological malignancies
Kotla, V., Goel, S., Nischal, S., Heuck, C., Vivek, K., Das, B., & Verma, A. (2009) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-2-36 · Cited by 467
Microglial Cells: The Main HIV-1 Reservoir in the Brain
Wallet, C., De Rovere, M., Van Assche, J., Daouad, F., De Wit, S., Gautier, V., Mallon, P. W. G., Marcello, A., Van Lint, C., Rohr, O., et al. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00362 · Cited by 368
Villitis of unknown etiology: noninfectious chronic villitis in the placenta
Redline, R. W. (2007) · Human Pathology · doi:10.1016/j.humpath.2007.05.025 · Cited by 361
O'Day, S. J., Hamid, O., & Urba, W. J. (2007) · Cancer · doi:10.1002/cncr.23086 · Cited by 309
Chen, S., Lee, L.-F., Fisher, T. S., Jessen, B., Elliott, M., Evering, W., Logronio, K., Tu, G. H., Tsaparikos, K., Li, X., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0118 · Cited by 277
OX40, OX40L and Autoimmunity: a Comprehensive Review
Webb, G. J., Hirschfield, G. M., & Lane, P. J. L. (2016) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-015-8498-3 · Cited by 277
Costimulatory and Coinhibitory Receptor Pathways in Infectious Disease
Attanasio, J., & Wherry, E. J. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.022 · Cited by 256
(2019) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2018.07.001 · Cited by 245
Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view
Boswell, C. A., & Brechbiel, M. W. (2007) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2007.04.001 · Cited by 241
Maternal Acceptance of the Fetus: True Human Tolerance
Guleria, I., & Sayegh, M. H. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.6.3345 · Cited by 235
Dostalek, M., Gardner, I., Gurbaxani, B. M., Rose, R. H., & Chetty, M. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-012-0027-4 · Cited by 230
An immunological insight into the origins of pre-eclampsia
Laresgoiti-Servitje, E., Gomez-Lopez, N., & Olson, D. M. (2010) · Human Reproduction Update · doi:10.1093/humupd/dmq007 · Cited by 218
Mould, D. R., & Green, B. (2010) · BioDrugs · doi:10.2165/11530560-000000000-00000 · Cited by 207
Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade
Buchbinder, E., & Hodi, F. S. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80012 · Cited by 178
“T cells, one of the key mediators of the immune response, require costimulation for activation and can be inactivated by inhibitory signals (10).”
BackgroundCombination immunotherapy approaches
Drake, C. G. (2012) · Annals of Oncology · doi:10.1093/annonc/mds262 · Cited by 168
A Link between PDL1 and T Regulatory Cells in Fetomaternal Tolerance
Habicht, A., Dada, S., Jurewicz, M., Fife, B. T., Yagita, H., Azuma, M., Sayegh, M. H., & Guleria, I. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.8.5211 · Cited by 165
Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
Herzberg, B., Campo, M. J., & Gainor, J. F. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0189 · Cited by 164
van Duin, D., Allore, H. G., Mohanty, S., Ginter, S., Newman, F. K., Belshe, R. B., Medzhitov, R., & Shaw, A. C. (2007) · The Journal of Infectious Diseases · doi:10.1086/516788 · Cited by 159
Role of PD-1 co-inhibitory pathway in HIV infection and potential therapeutic options
Velu, V., Shetty, R. D., Larsson, M., & Shankar, E. M. (2015) · Retrovirology · doi:10.1186/s12977-015-0144-x · Cited by 170
Liu, H., Shen, J., & Lü, K. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.02.128 · Cited by 157
Cytotoxic T-Lymphocyte–Associated Antigen-4
Salama, A. K. S., & Hodi, F. S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2232 · Cited by 149
Manda, K., Glasow, A., Paape, D., & Hildebrandt, G. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00102 · Cited by 163
Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management
Tang, L., Wang, J., Lin, N., Zhou, Y., He, W., Liu, J., & Ma, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.800879 · Cited by 144
BCL11B is required for positive selection and survival of double-positive thymocytes
Albu, D. I., Feng, D., Bhattacharya, D., Jenkins, N. A., Copeland, N. G., Liu, P., & Avram, D. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070863 · Cited by 134
T-Cell Costimulation and Coinhibition in Atherosclerosis
Gotsman, I., Sharpe, A. H., & Lichtman, A. H. (2008) · Circulation Research · doi:10.1161/circresaha.108.182428 · Cited by 140
Self-citationTsai, H.-F., & Hsu, P. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0341-0 · Cited by 145
Dendritic cell vaccines in melanoma: From promise to proof?
Lesterhuis, W. J., Aarntzen, E. H. J. G., de Vries, I. J. M., Schuurhuis, D. H., Figdor, C. G., Adema, G. J., & Punt, C. J. A. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.12.007 · Cited by 124
Preclinical and clinical safety of monoclonal antibodies
Tabrizi, M. A., & Roskos, L. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.05.010 · Cited by 116
Yiu, H., Graham, A. L., & Stengel, R. F. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045027 · Cited by 122
CD28 Co-Stimulation Down Regulates Th17 Development
Bouguermouh, S., Fortin, G., Baba, N., Rubio, M., & Sarfati, M. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005087 · Cited by 101
Co-stimulatory and co-inhibitory pathways in cancer immunotherapy
O’Neill, R., & Cao, X. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2019.03.003 · Cited by 110
Mascelli, M. A., Zhou, H., Sweet, R., Getsy, J., Davis, H. M., Graham, M., & Abernethy, D. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006298360 · Cited by 100
Mori, S., & Fujiyama, S. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i36.10274 · Cited by 105
Maruse, Y., Kawano, S., Jinno, T., Matsubara, R., Goto, Y., Kaneko, N., Sakamoto, T., Hashiguchi, Y., Moriyama, M., Toyoshima, T., et al. (2018) · International Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.ijom.2018.01.004 · Cited by 96
DEPTOR at the Nexus of Cancer, Metabolism, and Immunity
Caron, A., Briscoe, D. M., Richard, D., & Laplante, M. (2018) · Physiological Reviews · doi:10.1152/physrev.00064.2017 · Cited by 93
Physiologic and aberrant regulation of memory T-cell trafficking by the costimulatory molecule CD28
Mirenda, V., Jarmin, S. J., David, R., Dyson, J., Scott, D., Gu, Y., Lechler, R. I., Okkenhaug, K., & Marelli‐Berg, F. M. (2006) · Blood · doi:10.1182/blood-2006-10-050724 · Cited by 90
Signaling Signatures and Functional Properties of Anti-Human CD28 Superagonistic Antibodies
Waibler, Z., Sender, L. Y., Merten, C., Hartig, R., Kliche, S., Gunzer, M., Reichardt, P., Kalinke, U., & Schraven, B. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001708 · Cited by 79
“from stimulation of so called co-stimulatory molecules [1,2].”
BackgroundMiller, P. L., & Carson, T. L. (2020) · Gut Pathogens · doi:10.1186/s13099-020-00381-6 · Cited by 85
Wolchok, J. D. (2012) · Annals of Oncology · doi:10.1093/annonc/mds258 · Cited by 81
Immune-Related Adverse Events: Pneumonitis
Zhong, L., Altan, M., Shannon, V. R., & Sheshadri, A. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-41008-7_13 · Cited by 86
The Role of Costimulation Blockade in Solid Organ and Islet Xenotransplantation
Samy, K. P., Butler, J. R., Li, P., Cooper, D. K. C., & Ekser, B. (2017) · Journal of Immunology Research · doi:10.1155/2017/8415205 · Cited by 74
New Insights into the Role of the Immune Microenvironment in Breast Carcinoma
de la Cruz‐Merino, L., Barco-Sánchez, A., Henao, F., Fernández, E. N., Benítez, A. V., Molina, J. B., Martínez-Peinado, A., López, A. G., Borrego, M. R., de Villena, M. C. M., et al. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/785317 · Cited by 83
Co-stimulatory modulation in rheumatoid arthritis: The role of (CTLA4-Ig) abatacept
Fiocco, U., Sfriso, P., Oliviero, F., Pagnin, E., Scagliori, E., Campana, C., Dainese, S., Cozzi, L., & Punzi, L. (2008) · Autoimmunity Reviews · doi:10.1016/j.autrev.2008.07.035 · Cited by 74
Rüter, J., Barnett, B. G., Kryczek, I., Brumlik, M. J., Daniel, B. J., Coukos, G., Zou, W., & Curiel, T. J. (2009) · Frontiers in bioscience · doi:10.2741/3338 · Cited by 67
Roep, B. O. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1394.018 · Cited by 70
Zhu, Z., & Dong, W. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s160493 · Cited by 65
CAR T-Cell Therapy for Patients with Multiple Myeloma: Current Evidence and Challenges
Rendo, M. J., Joseph, J. J., Phan, L. M., & DeStefano, C. B. (2022) · Blood and Lymphatic Cancer Targets and Therapy · doi:10.2147/blctt.s327016 · Cited by 78
New Reagents on the Horizon for Immune Tolerance
St. Clair, E. W., Turka, L. A., Saxon, A., Matthews, J. B., Sayegh, M. H., Eisenbarth, G. S., & Bluestone, J. (2007) · Annual Review of Medicine · doi:10.1146/annurev.med.58.061705.145449 · Cited by 62
Zhao, W., Dong, Y., Wu, C., Ma, Y., Jin, Y., & Ji, Y. (2015) · Experimental Cell Research · doi:10.1016/j.yexcr.2015.12.002 · Cited by 65
Immune checkpoint inhibitors for cancer treatment
Park, J., Kwon, M., & Shin, E. (2016) · Archives of Pharmacal Research · doi:10.1007/s12272-016-0850-5 · Cited by 63
Lönnroth, C., Andersson, M., Arvidsson, A., Nordgren, S., Brevinge, H., Lagerstedt, K., & Lundholm, K. (2008) · PubMed · Cited by 66
Cancer Immunosurveillance by T Cells
(2019) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2018.08.001 · Cited by 58
Soto, P. C., Stein, L. L., Hurtado-Ziola, N., Hedrick, S. M., & Varki, A. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903420 · Cited by 56
Appel, G. B., Radhakrishnan, J., & D’Agati, V. D. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4160-6193-9.10032-6 · Cited by 59
Grinyo, J. M., Alberú, J., Contieri, F. L. C., Manfro, R. C., Mondragón, G., Nainan, G., Rial, M. D. C., Steinberg, S., Vincenti, F. G., Dong, Y., et al. (2012) · Transplant International · doi:10.1111/j.1432-2277.2012.01535.x · Cited by 55
Oncogenic pathways that affect antitumor immune response and immune checkpoint blockade therapy
Zhao, X., & Subramanian, S. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.07.004 · Cited by 53
The problems and promises of research into human immunology and autoimmune disease
Roep, B. O., Buckner, J. H., Sawcer, S. J., Toes, R. E. M., & Zipp, F. (2012) · Nature Medicine · doi:10.1038/nm.2626 · Cited by 56
Stahl, M. F., & Zeidan, A. M. (2017) · Cancer · doi:10.1002/cncr.30585 · Cited by 57
Adamson, C., & Babu (2012) · Core evidence · doi:10.2147/ce.s29001 · Cited by 54
On the way to find a cure: Purging latent HIV-1 reservoirs
Schwartz, C., Bouchat, S., Marban, C., Gautier, V., Lint, C. M. V., Rohr, O., & Douce, V. L. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.07.001 · Cited by 50
Lozano, E., Mena, M.-P., Díaz, T., Martin-Antonio, B., León, S., Rodríguez-Lobato, L.-G., Oliver-Caldés, A., Cibeira, M. T., Bladé, J., Prat, A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3673 · Cited by 47
Leblay, N., Maity, R., Hasan, F., & Neri, P. E. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00636 · Cited by 53
Biology and Clinical Applications of CD40 in Cancer Treatment
Fonsatti, E., Maio, M., Altomonte, M., & Hersey, P. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.09.002 · Cited by 43
Therapeutic plasticity of stem cells and allograft tolerance
Sordi, V., & Piemonti, L. (2011) · Cytotherapy · doi:10.3109/14653249.2011.583476 · Cited by 42
de la Cruz‐Merino, L., Lejeune, M., Fernández, E. N., Henao, F., López, A. G., Illescas-Vacas, A., Provencio, M., Callau, C., & Álvaro, T. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/756353 · Cited by 43
Ganesan, P., Piha-Paul, S. A., Naing, A., Falchook, G. S., Wheler, J. J., Jankú, F., Zinner, R., Laday, S., Kies, M. S., & Tsimberidou, A. M. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-0013-1 · Cited by 40
Zhou, H., & Davis, H. M. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.05.014 · Cited by 38
Rich, R. R., & Chaplin, D. (2019) · Elsevier eBooks · doi:10.1016/b978-0-7020-6896-6.00001-6 · Cited by 57
Sattiraju, A., & Mintz, A. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-16908-4_2 · Cited by 41
Inhibition of ADP Ribosylation Prevents and Cures Helicobacter -Induced Gastric Preneoplasia
Toller, I. M., Altmeyer, M., Kohler, E., Hottiger, M. O., & Mueller, A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0528 · Cited by 39
Effects of Aluminum on Immune Functions of Cultured Splenic T and B Lymphocytes in Rats
She, Y., Wang, N., Chen, C., Zhu, Y., Xia, S., Hu, C., & Li, Y. (2012) · Biological Trace Element Research · doi:10.1007/s12011-011-9307-3 · Cited by 37
“Splenic T and B lymphocytes play an essential role in maintaining immunologic homeostasis of the spleen, and the changes of them can indicate cellular and humoral immune state [21, 22].”
BackgroundAntczak, A. J., Pastuszak‐Lewandoska, D., Górski, P., Domańska, D., Migdalska‐Sęk, M., Czarnecka, K. H., Nawrot, E., Kordiak, J., & Brzeziańska‐Lasota, E. (2013) · BioMed Research International · doi:10.1155/2013/576486 · Cited by 44
The three‐signal hypothesis of lymphocyte activation/targets for immunosuppression
Göral, S. (2011) · Dialysis & Transplantation · doi:10.1002/dat.20527 · Cited by 36
Segler, A., & Tsimberidou, A. M. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1874-2 · Cited by 42
Introduction to Costimulation and Costimulatory Molecules
Mir, M. A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-802585-7.00001-7 · Cited by 59
Importance of Feedback and Feedforward Loops to Adaptive Immune Response Modeling
Rahman, A., Tiwari, A., Narula, J., & Hickling, T. P. (2018) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12352 · Cited by 43
T Cell Calcium Signaling Regulation by the Co-Receptor CD5
Freitas, C. M. T., Johnson, D. K., & Weber, K. S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051295 · Cited by 33
Immune Checkpoint Blockade in Breast Cancer Therapy
Bu, X., Yao, Y., & Li, X. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-6020-5_18 · Cited by 36
CD137: A checkpoint regulator involved in atherosclerosis
Söderström, L. Å., Tarnawski, L., & Olofsson, P. S. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.03.007 · Cited by 35
Sullivan, C., Barry, F., Ritter, T., O’Flatharta, C., Howard, L., Shaw, G., Anegón, I., & Murphy, M. J. (2013) · Stem Cells and Development · doi:10.1089/scd.2013.0248 · Cited by 35
The impact of biologic response modifiers on hepatitis B virus infection
Carroll, M. B. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.554810 · Cited by 31
The Ipilimumab Lesson in Melanoma: Achieving Long-Term Survival
Delyon, J., Maio, M., & Lebbé, C. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.02.005 · Cited by 35
García, C., Benakanakere, M. R., Alard, P., Kosiewicz, M. M., Kinane, D. F., & Martin, M. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.12.8363 · Cited by 34
Findlay, L., Sharp, G., Fox, B., Ball, C., Robinson, C. J., Bird, C., Stebbings, R., Eastwood, D., Wadhwa, M., Poole, S., et al. (2011) · Cytokine · doi:10.1016/j.cyto.2011.03.019 · Cited by 29
Whitman, E., & Barber, A. (2014) · Molecular Immunology · doi:10.1016/j.molimm.2014.07.015 · Cited by 37
Fyhrquist, N., Alenius, H. T., & Lauerma, A. (2007) · Dermatologic Clinics · doi:10.1016/j.det.2007.06.002 · Cited by 29
Kim, M., Choe, Y., & Lee, S. (2022) · Immune Network · doi:10.4110/in.2022.22.e8 · Cited by 31
Chitale, S., & Moots, R. J. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.1.115 · Cited by 28
T Lymphocyte–Based Cancer Immunotherapeutics
Borrie, A. E., & Vareki, S. M. (2018) · International review of cytology · doi:10.1016/bs.ircmb.2018.05.010 · Cited by 29
Immunotherapy and Immune Evasion in Prostate Cancer
Thakur, A. B., Vaishampayan, U. N., & Lum, L. G. (2013) · Cancers · doi:10.3390/cancers5020569 · Cited by 28
ICOS-LICOS interaction is critically involved in TGN1412-mediated T-cell activation
Weissmüller, S., Semmler, L. Y., Kalinke, U., Christians, S., Müller-Berghaus, J., & Waibler, Z. (2012) · Blood · doi:10.1182/blood-2011-12-401083 · Cited by 26
Lozano, E., Díaz, T., Mena, M.-P., Suñé, G., Calvo, X., Calderón, M., Pérez-Amill, L., Rodríguez, V., Perez-Galan, P., Roué, G., et al. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701622 · Cited by 26
Cui, N., Wang, H., Long, Y., & Liu, D. (2013) · Critical Care · doi:10.1186/cc12836 · Cited by 25
Selection of human anti-CD28 scFvs from a T-NHL related scFv library using ribosome display
Rothe, A., Nathanielsz, A., Hosse, R. J., Oberhauser, F., von Strandmann, E. P., Engert, A., Hudson, P. J., & Power, B. E. (2007) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2007.05.012 · Cited by 25
Zhuang, C., She, Y., Zhang, H., Song, M., Han, Y., Li, Y., & Zhu, Y. (2018) · Toxicology Letters · doi:10.1016/j.toxlet.2018.01.007 · Cited by 25
Ippoliti, G., D'Armini, Lucioni, M., Marjieh, & Viganò (2012) · Biologics · doi:10.2147/btt.s27565 · Cited by 23
Immune-Related Adverse Events: Pneumonitis
Jain, A., Shannon, V. R., & Sheshadri, A. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-02505-2_6 · Cited by 25
CD28 and ICOS in immune regulation: Structural insights and therapeutic targeting
Upadhyay, S., Kaur, B., & Gabr, M. T. (2025) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2025.130310 · Cited by 20
Metadata
- Authors
- Sharpe, A. H., & Abbas, A. K.
- Affiliations
- Harvard University (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-09-07
- Volume
- 355
- Issue
- 10
- Pages
- 973-975
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2135741926
- Cited by
- 206
- References
- 7
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 3 · 2023: 4 · 2022: 8 · 2021: 4 · 2020: 9 · 2019: 10 · 2018: 15 · 2017: 10 · 2016: 11 · 2015: 12 · 2014: 8 · 2013: 14 · 2012: 17
- FWCI
- 6.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- T cell costimulation, T cell activation, self-tolerance, anti-CD28 monoclonal antibody, autoimmunity, T cell biology
- MeSH terms
- Animals, Antibodies, Monoclonal, Antigen-Presenting Cells, Humans, Immune Tolerance, Lymphocyte Activation, T-Lymphocytes, Cytokines, CD28 Antigens, Models, Animal, Mice, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.